EP2176429A1 - Predictive marker for egfr inhibitor treamtent - Google Patents
Predictive marker for egfr inhibitor treamtentInfo
- Publication number
- EP2176429A1 EP2176429A1 EP08785424A EP08785424A EP2176429A1 EP 2176429 A1 EP2176429 A1 EP 2176429A1 EP 08785424 A EP08785424 A EP 08785424A EP 08785424 A EP08785424 A EP 08785424A EP 2176429 A1 EP2176429 A1 EP 2176429A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- patients
- cancer
- treatment
- gene
- egfr inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- TarcevaTM was given orally once per day at a dose of 150 mg until disease progression, intolerable toxicities or death.
- the selection of this dose was based on pharmacokinetic parameters, as well as the safety and tolerability profile of this dose observed in Phase I, II and III trials in heavily pre-treated patients with advanced cancer.
- Drug levels seen in the plasma of patients with cancer receiving the 150 mg/day dose were consistently above the average plasma concentration of 500 ng / ml targeted for clinical efficacy.
- BR.21 showed a survival benefit with this dose.
- Affymetrix HG-U 133 A microarrays contain over 22,000 probe sets targeting approximately 18,400 transcripts and variants which represent about 14,500 well- characterized genes.
- Step 5 was a robustness analysis. The goal was to generate a qualified list of candidate markers that do not heavily depend on the pre-processing methods and statistical assumptions. It consisted in reiterating the analysis with different methodological approaches and intersecting the list of candidates.
- Descriptive exploratory analysis was performed to identify potential bias and major sources of variability.
- a set of covariates with a potential impact on gene expression profiles was screened. It comprised both technical and clinical variables.
- Technical covariates included: date of RNA processing (later referred to as batch), RIN (as a measure of RNA quality/integrity), Operator and Center of sample collection.
- Clinical covariates included: Histology type, smoking status, tumour grade, performance score (Oken, M.M., et al., Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol, 1982. 5(6): p. 649-55), demographic data, responder status and clinical benefit status.
- the analysis tools included univariate ANOVA and principal component analysis. For each of these covariates, univariate ANOVA was applied independently to each probe-set.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08785424A EP2176429A1 (en) | 2007-08-14 | 2008-08-07 | Predictive marker for egfr inhibitor treamtent |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07114305 | 2007-08-14 | ||
EP08785424A EP2176429A1 (en) | 2007-08-14 | 2008-08-07 | Predictive marker for egfr inhibitor treamtent |
PCT/EP2008/006518 WO2009021679A1 (en) | 2007-08-14 | 2008-08-07 | Predictive marker for egfr inhibitor treamtent |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2176429A1 true EP2176429A1 (en) | 2010-04-21 |
Family
ID=39789783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08785424A Ceased EP2176429A1 (en) | 2007-08-14 | 2008-08-07 | Predictive marker for egfr inhibitor treamtent |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2176429A1 (es) |
JP (1) | JP2010535520A (es) |
KR (1) | KR20100037633A (es) |
CN (1) | CN101802221A (es) |
AU (1) | AU2008286412A1 (es) |
BR (1) | BRPI0815372A2 (es) |
CA (1) | CA2695318A1 (es) |
MX (1) | MX2010001572A (es) |
WO (1) | WO2009021679A1 (es) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5646249A (en) * | 1994-02-28 | 1997-07-08 | The United States Of America As Represented By The Department Of Health And Human Services | Isolation and characterization of a novel chaperone protein |
CA2527321A1 (en) * | 2003-05-30 | 2004-12-23 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
BRPI0410634A (pt) * | 2003-05-30 | 2006-06-13 | Astrazeneca Uk Ltd | processo |
-
2008
- 2008-08-07 CA CA2695318A patent/CA2695318A1/en not_active Abandoned
- 2008-08-07 KR KR1020107003252A patent/KR20100037633A/ko not_active Application Discontinuation
- 2008-08-07 WO PCT/EP2008/006518 patent/WO2009021679A1/en active Application Filing
- 2008-08-07 JP JP2010520467A patent/JP2010535520A/ja active Pending
- 2008-08-07 MX MX2010001572A patent/MX2010001572A/es not_active Application Discontinuation
- 2008-08-07 CN CN200880102973A patent/CN101802221A/zh active Pending
- 2008-08-07 AU AU2008286412A patent/AU2008286412A1/en not_active Abandoned
- 2008-08-07 BR BRPI0815372A patent/BRPI0815372A2/pt not_active IP Right Cessation
- 2008-08-07 EP EP08785424A patent/EP2176429A1/en not_active Ceased
Non-Patent Citations (1)
Title |
---|
See references of WO2009021679A1 * |
Also Published As
Publication number | Publication date |
---|---|
MX2010001572A (es) | 2010-03-15 |
BRPI0815372A2 (pt) | 2019-09-24 |
WO2009021679A1 (en) | 2009-02-19 |
KR20100037633A (ko) | 2010-04-09 |
JP2010535520A (ja) | 2010-11-25 |
CA2695318A1 (en) | 2009-02-19 |
CN101802221A (zh) | 2010-08-11 |
AU2008286412A1 (en) | 2009-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009021674A1 (en) | Predictive markers for egfr inhibitor treatment | |
US20110218212A1 (en) | Predictive markers for egfr inhibitors treatment | |
EP2179057B1 (en) | Predictive marker for egfr inhibitor treatment | |
WO2009021683A2 (en) | Predictive marker for egfr inhibitor treatment | |
US20110195982A1 (en) | Predictive marker for egfr inhibitor treatment | |
US9121067B2 (en) | Predictive marker for EGFR inhibitor treatment | |
US20110312981A1 (en) | Predictive marker for egfr inhibitor treatment | |
EP2176429A1 (en) | Predictive marker for egfr inhibitor treamtent | |
WO2009021680A1 (en) | Predictive marker for egfr inhibitor treatment | |
US20110184004A1 (en) | Predictive marker for egfr inhibitor treatment | |
WO2009021677A1 (en) | Predictive marker for egfr inhibitor treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100315 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
17Q | First examination report despatched |
Effective date: 20100610 |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20110711 |